ArticleCancer science2026
Myofibroblast-Like CAFs in Metastatic Lymph Nodes Drive Tumor Stemness and Poor Prognosis in Head and Neck Cancer.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lymph node (LN) metastasis is one of the major prognostic factors in head and neck squamous cell carcinoma (HNSCC), and treatment sensitivity often differs between primary tumors and metastatic LNs. Beyond tumor cell-intrinsic differences, heterogeneity of the tumor microenvironment may contribute to these discrepancies. We focused on cancer-associated fibroblasts (CAFs) and compared CAFs derived from primary tumors and corresponding LN metastases. Bulk tissue analysis showed higher expression of myofibroblast-related genes (ACTA2, MYL9, MYLK) and increased COMP expression in metastatic LNs. Thirteen paired CAFs were established and serially passaged. Compared with primary tumor-derived CAFs (PT-CAFs), metastatic LN-derived CAFs (LN-CAFs) exhibited reduced proliferative and migratory capacities, but enhanced collagen gel contraction, while promoting tumor cell-sphere formation and cancer stem cell marker expression. These findings support a myofibroblast-like phenotype in LN-CAFs. In line with this, PT-CAFs showed greater induction of myofibroblast-related genes in response to TGF-β, but not IL-6 stimulation, suggesting that LN-CAFs had already differentiated toward a myofibroblast-like phenotype. RNA sequencing of five paired CAFs confirmed a myofibroblastic transcriptional profile, with enrichment of fibrosis-related and malignant trait-associated pathways, including epithelial-mesenchymal transition (EMT), hypoxia, and p53 signaling. Finally, least absolute shrinkage and selection operator-based prognostic models validated in The Cancer Genome Atlas (TCGA) cohort using genes upregulated in LN-CAFs were significantly associated with worse progression-free survival and overall survival. These results demonstrate that CAF heterogeneity depends on tumor localization and is linked to therapeutic resistance and poor clinical outcomes in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.